Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00857532
Recruitment Status : Completed
First Posted : March 6, 2009
Results First Posted : March 11, 2013
Last Update Posted : March 11, 2013
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Avid Radiopharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: florbetapir F 18 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Study Start Date : January 2009
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Normal cognitive performance
Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
 Drug: florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Other Names:
  • 18F-AV-45
  • Amyvid
  • florbetapir
Experimental: Mild cognitive deficits
Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
 Drug: florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Other Names:
  • 18F-AV-45
  • Amyvid
  • florbetapir
Experimental: Severe cognitive impairment
Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
 Drug: florbetapir F 18
10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Other Names:
  • 18F-AV-45
  • Amyvid
  • florbetapir


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Mean Cortical Amyloid Burden [ Time Frame: 50-60 min after injection ]
    Standardized uptake value ratios (SUVR) were calculated and compared between subjects with PD and controls. Subjects with Parkinson's Disease (PD) were stratified into one of three groups based on performance on the age and education adjusted Mattis Dementia Rating Scale (DRS-2). The age and education adjusted DRS-2 ranges from 0 (lowest cognitive function) to 20 (highest cognitive function). SUVR is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the whole cerebellum. SUVR values higher than 1 indicate greater amyloid burden in the predefined cortical regions as compared to cerebellum whereas scores less than 1 indicate the opposite. This outcome measure only reports data from the subjects analyzed in this study, the data from normal controls was obtained from a pre-existing database and is not reported here.


Secondary Outcome Measures :
  1. Correlation Between Global Amyloid Burden and Clinical Measures of Cognitive Decline. [ Time Frame: 50-60 min after injection ]
    Correlation between amyloid burden (global florbetapir SUVR) and cognitive decline (DRS-2 score) was determined using Spearman's rank order correlation method where SUVR was the dependent variable and the DRS-2 score was the independent variable. This analysis was performed for total DRS-2 score and the five DRS-2 subscale scores. The subscales (score range) are: Attention (0-37), Initiation/Perseveration (0-37), Construction (0-6), Conceptualization (0-39) and Memory (0-25). The total DRS-2 score is the sum of the subscale scores and ranges from 0-144. Higher DRS-2 scores indicate greater cognitive function.

  2. Correlation of Florbetapir SUVR With CSF Biomarker Values [ Time Frame: 50-60 min after injection ]
    Correlation between amyloid burden (florbetapir SUVR) and cerebrospinal fluid (CSF) biomarker values (amyloid beta, tau and phospho-tau) was determined using Spearman's rank order correlation in a subset of subjects undergoing CSF analysis where SUVR was the dependent variable and CSF biomarker values were the independent variables.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects may be enrolled if they (inclusion criteria):

    • Are males or females ≥60 years of age
    • Meet research diagnostic criteria for Parkinson's disease:

    • Diagnosis of a parkinsonian syndrome

      • Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed and amplitude of repetitive actions)
      • At least one of the following: muscle rigidity, rest tremor, postural instability not due to visual, vestibular, cerebellar or proprioceptive causes

    • Supportive criteria for diagnosis of PD (two or more required)

      • Unilateral onset of symptoms and persistent asymmetry
      • Rest tremor present
      • Progressive illness
      • Excellent response to levodopa with dyskinesias
      • Levodopa response for 5 years or more
      • Clinical course of 10 years or more
    • Have the ability to lie flat and tolerate a 10 minute PET scan.

Exclusion Criteria:

  • Subjects may not be enrolled if any of the following are present (exclusion criteria):

    • History of repeated strokes, repeated head injury, definite encephalitis
    • Use of neuroleptics at onset of symptoms
    • Sustained remission
    • Strictly unilateral feature persisting > three years after onset
    • Significant supranuclear gaze palsy
    • Cerebellar, pyramidal and early severe autonomic findings
    • Early severe dementia suggesting a diagnosis of dementia with Lewy bodies (DLB)
    • Imaging study showing structural abnormality that could explain parkinsonism
    • Negative response to an adequate levodopa trial
    • Current clinically significant psychiatric disease that prohibits providing informed consent or participation in the study
    • Current clinically significant endocrine or metabolic disease, pulmonary,
    • Women of childbearing potential who are not two or more years post menopausal or surgically sterilized
    • Have received any investigational medications, or have participated in a trial with investigational medications within the last 30 days
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00857532


Locations
Layout table for location information
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Avid Radiopharmaceuticals
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Layout table for investigator information
Study Director: Chief Medical Officer Avid Radiopharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier: NCT00857532     History of Changes
Other Study ID Numbers: 18F-AV-45-A12
5R43NS063607-02 ( U.S. NIH Grant/Contract )
First Posted: March 6, 2009    Key Record Dates
Results First Posted: March 11, 2013
Last Update Posted: March 11, 2013
Last Verified: February 2013

Keywords provided by Avid Radiopharmaceuticals:
amyloid burden
Parkinson's disease
florbetapir PET
amyloid PET imaging

Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Amyloidosis
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Proteostasis Deficiencies
Metabolic Diseases